Drugs / Levodopa formulation
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05435729 Background | May → Nov 2022 | Parkinson disease, drug-induced dyskinesia | Sumitomo Pharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Levodopa formulation | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05435729 ↗ |